Stocks · News reference
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
This Occidental Petroleum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral COP; Buy TLSA ($7), OXY ($73), NRSN ($8); Sell SM ($35).
BTIG Initiates Coverage On Tiziana Life Sciences with Buy Rating, Announces Price Target of $7
BTIG analyst Thomas Shrader initiates coverage on Tiziana Life Sciences (NASDAQ:TLSA) with a Buy rating and announces Price Target of $7.